U.S. patent application number 16/795816 was filed with the patent office on 2020-06-18 for systems and methods for increasing absorbent capacity of a dressing.
The applicant listed for this patent is KCI Licensing, Inc.. Invention is credited to Christopher Brian LOCKE, Timothy Mark ROBINSON.
Application Number | 20200188563 16/795816 |
Document ID | / |
Family ID | 52596605 |
Filed Date | 2020-06-18 |
![](/patent/app/20200188563/US20200188563A1-20200618-D00000.png)
![](/patent/app/20200188563/US20200188563A1-20200618-D00001.png)
![](/patent/app/20200188563/US20200188563A1-20200618-D00002.png)
![](/patent/app/20200188563/US20200188563A1-20200618-D00003.png)
![](/patent/app/20200188563/US20200188563A1-20200618-D00004.png)
![](/patent/app/20200188563/US20200188563A1-20200618-D00005.png)
United States Patent
Application |
20200188563 |
Kind Code |
A1 |
ROBINSON; Timothy Mark ; et
al. |
June 18, 2020 |
SYSTEMS AND METHODS FOR INCREASING ABSORBENT CAPACITY OF A
DRESSING
Abstract
Systems and methods for managing fluid absorption from a tissue
site are described. A dressing having an absorbent is positioned
proximate the tissue site to receive fluid from the tissue site. A
reduced-pressure source is fluidly coupled to the dressing and
supplies reduced pressure to the dressing. The reduced pressure is
periodically decreased to distribute fluid in the absorbent and
managed fluid absorption. The system includes a reduced-pressure
source and a container having an upstream layer, a downstream
layer, and an absorbent between the upstream layer and the
downstream layer. The system also includes a sealing member for
forming a therapeutic environment having the container and a
controller configured to operate the reduced pressure source to
intermittently supply reduced pressure to the therapeutic
environment and periodically decrease the reduced pressure in the
therapeutic environment.
Inventors: |
ROBINSON; Timothy Mark;
(Shillingstone, GB) ; LOCKE; Christopher Brian;
(Bournemouth, GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
KCI Licensing, Inc. |
San Antonio |
TX |
US |
|
|
Family ID: |
52596605 |
Appl. No.: |
16/795816 |
Filed: |
February 20, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14619743 |
Feb 11, 2015 |
10610623 |
|
|
16795816 |
|
|
|
|
61939958 |
Feb 14, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61F 13/00042 20130101;
A61M 2205/3331 20130101; A61M 1/0037 20130101; A61F 13/00017
20130101; A61F 13/0209 20130101; A61F 13/00068 20130101; A61M
1/0096 20140204; A61F 13/0216 20130101; A61M 1/0088 20130101 |
International
Class: |
A61M 1/00 20060101
A61M001/00; A61F 13/02 20060101 A61F013/02; A61F 13/00 20060101
A61F013/00 |
Claims
1.-12. (canceled)
13. A method for increasing the fluid capacity of an absorbent, the
method comprising: positioning a manifold adjacent a tissue site;
positioning the absorbent proximate the manifold; placing a drape
over the absorbent and the manifold; fluidly coupling a
reduced-pressure source to the manifold; compressing the absorbent
by supplying reduced pressure to the tissue site; and expanding the
absorbent by periodically decreasing the reduced pressure.
14. The method of claim 13, wherein the absorbent is a
superabsorbent polymer.
15. The method of claim 13, wherein the absorbent is a
superabsorbent polymer enclosed between a first non-woven layer and
a second non-woven layer.
16. The method of claim 13, wherein the absorbent is a granular
superabsorbent polymer enclosed between a first non-woven layer and
a second non-woven layer.
17. The method of claim 13, wherein the absorbent is a
hydrogel.
18. The method of claim 13, wherein supplying reduced pressure
comprises supplying reduced pressure for periodic intervals of
time.
19. The method of claim 18, wherein the time is one minute.
20. The method of claim 13, wherein expanding the absorbent
comprises stopping the supply of reduced pressure for periodic
intervals of time.
21. The method of claim 20, wherein the time is one minute.
22. The method of claim 20, wherein the time is five minutes.
23. The method of claim 20, wherein the time is between about 1
minute and about 20 minutes.
24. The method of claim 13, wherein compressing the absorbent
comprises supplying reduced pressure until a pressure adjacent the
manifold is about a therapy pressure.
25. The method of claim 24, wherein expanding the absorbent
comprises stopping the supply of reduced pressure until the
pressure adjacent the manifold is about an ambient pressure.
26. The method of claim 24, wherein expanding the absorbent
comprises stopping the supply of reduced pressure until the
pressure adjacent the manifold is about a nominal pressure.
27. The method of claim 13, wherein decreasing the reduced pressure
comprises delivering ambient air to the tissue site.
28.-44. (canceled)
Description
RELATED APPLICATIONS
[0001] This application is a divisional of U.S. patent application
Ser. No. 14/619,743, filed Feb. 11, 2015, which claims priority to
U.S. Provisional Patent Application No. 61/939,958, filed Feb. 14,
2014, entitled "SYSTEMS AND METHODS FOR INCREASING ABSORBENT
CAPACITY OF A DRESSING," which are hereby incorporated by
reference.
TECHNICAL FIELD
[0002] The present disclosure relates generally to absorbent
dressings, and more particularly, but without limitation, to a
method for increasing an absorbent capacity of a dressing.
BACKGROUND
[0003] Clinical studies and practice have shown that reducing
pressure in proximity to a tissue site can augment and accelerate
growth of new tissue at the tissue site. The applications of this
phenomenon are numerous, but it has proven particularly
advantageous for treating wounds. Regardless of the etiology of a
wound, whether trauma, surgery, or another cause, proper care of
the wound is important to the outcome. Treatment of wounds with
reduced pressure is commonly referred to as "reduced-pressure
therapy," but may also be known by other names, including "negative
pressure wound therapy" and "vacuum therapy," for example.
Reduced-pressure therapy may provide a number of benefits,
including migration of epithelial and subcutaneous tissues,
improved blood flow, and micro-deformation of tissue at a wound
site. Together, these benefits can increase development of
granulation tissue and reduce healing times.
[0004] While the clinical benefits of reduced-pressure therapy are
widely known, the cost and complexity of reduced-pressure therapy
can be a limiting factor in its application, and the development
and operation of reduced-pressure systems, components, and
processes continues to present significant challenges to
manufacturers, healthcare providers, and patients.
SUMMARY
[0005] According to an illustrative, non-limiting embodiment, a
method for managing fluid absorption from a tissue site is
described. A dressing having an absorbent may be positioned
proximate the tissue site to receive fluid from the tissue site. A
reduced-pressure source may be fluidly coupled to the dressing and
supply reduced pressure to the dressing. The reduced pressure may
be periodically decreased to distribute fluid in the absorbent.
[0006] According to another illustrative embodiment, a method for
increasing the fluid capacity of an absorbent is described. A
manifold may be positioned adjacent a tissue site, and the
absorbent may be positioned proximate the manifold. A drape may be
placed over the absorbent and the manifold. A reduced-pressure
source may be fluidly coupled to the manifold and may supply
reduced pressure to the tissue site. The reduced pressure may be
periodically decreased.
[0007] According to another illustrative embodiment, a system for
providing reduced pressure to a tissue site is described. The
system may include a reduced-pressure source and a container
configured to be positioned between the tissue site and the
reduced-pressure source. The container may include an upstream
layer formed from non-woven material, a downstream layer, and an
absorbent formed from a superabsorbent polymer disposed between the
upstream layer and the downstream layer. The system may also
include a sealing member configured to be sealed over the container
to form a therapeutic environment. The system may further include a
controller configured to operate the reduced pressure source to
intermittently supply reduced pressure to the therapeutic
environment and periodically decrease the reduced pressure in the
therapeutic environment.
[0008] Other aspects, features, and advantages of the illustrative
embodiments will become apparent with reference to the drawings and
detailed description that follow.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Illustrative embodiments are described in detail below with
reference to the attached drawings, which are incorporated by
reference herein, and wherein:
[0010] FIG. 1 is a partial sectional view of a system for providing
reduced-pressure therapy to a tissue site in accordance with some
embodiments;
[0011] FIG. 2 is graph of a pressure profile in a sealed
therapeutic environment provided by the system of FIG. 1;
[0012] FIG. 3 is graph of another pressure profile in a sealed
therapeutic environment provided by the system of FIG. 1;
[0013] FIG. 4 is graph of another pressure profile in a sealed
therapeutic environment provided by the system of FIG. 1;
[0014] FIG. 5 is a flow chart depicting logical operational steps
of a method for providing reduced-pressure therapy in accordance
with some embodiments;
[0015] FIG. 6 is a flow chart depicting logical operational steps
of another method for providing reduced-pressure therapy in
accordance with some embodiments; and
[0016] FIG. 7 is a flow chart depicting logical operational steps
of another method for providing reduced-pressure therapy in
accordance with some embodiments.
DETAILED DESCRIPTION
[0017] New and useful systems, methods, and apparatuses associated
with increasing a fluid capacity of an absorbent dressing in a
reduced-pressure environment are set forth in the appended claims.
Objectives, advantages, and a preferred mode of making and using
the systems, methods, and apparatuses may be understood best by
reference to the following detailed description in conjunction with
the accompanying drawings. The description provides information
that enables a person skilled in the art to make and use the
claimed subject matter, but may omit certain details already
well-known in the art. Moreover, descriptions of various
alternatives using terms such as "or" do not necessarily require
mutual exclusivity unless clearly required by the context. The
claimed subject matter may also encompass alternative embodiments,
variations, and equivalents not specifically described in detail.
The following detailed description should therefore be taken as
illustrative and not limiting.
[0018] The example embodiments may also be described herein in the
context of reduced-pressure therapy applications, but many of the
features and advantages are readily applicable to other
environments and industries. Spatial relationships between various
elements or to the spatial orientation of various elements may be
described as depicted in the attached drawings. In general, such
relationships or orientations assume a frame of reference
consistent with or relative to a patient in a position to receive
reduced-pressure therapy. However, as should be recognized by those
skilled in the art, this frame of reference is merely a descriptive
expedient rather than a strict prescription.
[0019] FIG. 1 is a partial section of a reduced-pressure therapy
system 100 illustrating details that may be associated with some
embodiments. In some embodiments, the reduced-pressure therapy
system 100 may include a dressing, such as a dressing 104, fluidly
coupled to a reduced-pressure source, such as a reduced-pressure
source 106 having a controller 107. In some embodiments, the
reduced-pressure source 106 may be fluidly coupled to the dressing
104 by a conduit, such as a tube 112, and a connector, such as a
connector 114. In some embodiments, a filter 132 may be disposed
within a fluid channel of the connector 114. The dressing 104 may
generally include a medical drape, such as a drape 108, an
absorbent pouch, such as the container 116, and a tissue interface,
such as a manifold 110. The drape 108 may be attached to an
epidermis 118. In some embodiments, the drape 108 can substantially
prevent the leakage of fluids while allowing vapor to egress
through the drape 108. In some embodiments, the dressing 104 having
the container 116 may be collectively referred to as an absorbent
dressing. In some embodiments, the container 116 may have an
absorbent, such as an absorbent 126, a first outer layer, such as
an upstream layer 128, and a second outer layer, such as a
downstream layer 130.
[0020] In general, components of the reduced-pressure therapy
system 100 may be coupled directly or indirectly to each other. For
example, the reduced-pressure source 106 may be directly coupled to
the connector 114 and indirectly coupled to the manifold 110
through the connector 114. Components may be fluidly coupled to
each other to provide a path for transferring fluids (such as
liquid and/or gas) between the components. In some embodiments,
components may be fluidly coupled with a tube, such as the tube
112, for example. A "tube," as used herein, broadly refers to a
tube, pipe, hose, conduit, or other structure with one or more
lumina adapted to convey fluids between two ends. Typically, a tube
is an elongated, cylindrical structure with some flexibility, but
the geometry and rigidity may vary. In some embodiments, components
may additionally or alternatively be coupled by virtue of physical
proximity, being integral to a single structure, or being formed
from the same piece of material. Coupling may also include
mechanical, thermal, electrical, or chemical coupling (such as a
chemical bond) in some contexts.
[0021] In operation, a tissue interface, such as the manifold 110,
may be placed within, over, on, against, or otherwise adjacent a
tissue site. For example, the manifold 110 may be placed against
the tissue site 102, and the drape 108 may be placed over the
manifold 110 and sealed to tissue proximate the tissue site 102.
Tissue proximate a tissue site is often undamaged epidermis
peripheral to the tissue site. Thus, the drape 108 can provide a
sealed therapeutic environment 124 proximate the tissue site 102.
The sealed therapeutic environment 124 may be substantially
isolated from the external environment, and the reduced-pressure
source 106 can reduce the pressure in the sealed therapeutic
environment 124. Reduced pressure applied across a tissue site
through a tissue interface in a sealed therapeutic environment can
induce macrostrain and microstrain in the tissue site, as well as
remove exudates and other fluids from the tissue site. The removed
exudates and other fluids can be collected in a container, such as
the container 116, and disposed of properly.
[0022] The fluid mechanics of using a reduced-pressure source to
reduce pressure in another component or location, such as within a
sealed therapeutic environment 124, can be mathematically complex.
However, the basic principles of fluid mechanics applicable to
reduced-pressure therapy are generally well-known to those skilled
in the art, and the process of reducing pressure may be described
illustratively herein as "delivering," "distributing," or
"generating" reduced pressure, for example.
[0023] In general, exudates and other fluids flow toward lower
pressure along a fluid path. This orientation is generally presumed
for purposes of describing various features and components of
reduced-pressure therapy systems herein. Thus, in the context of
reduced-pressure therapy, the term "downstream" typically implies a
position in a fluid path relatively closer to a reduced-pressure
source, and conversely, the term "upstream" implies a position
relatively further away from a reduced-pressure source. Similarly,
it may be convenient to describe certain features in terms of fluid
"inlet" or "outlet" in such a frame of reference. However, a fluid
path may also be reversed in some applications, such as by
substituting a positive-pressure source, and this descriptive
convention should not be construed as a limiting convention.
[0024] The term "tissue site" in this context broadly refers to a
wound or defect located on or within tissue, including but not
limited to, bone tissue, adipose tissue, muscle tissue, neural
tissue, dermal tissue, vascular tissue, connective tissue,
cartilage, tendons, or ligaments. A wound may include chronic,
acute, traumatic, subacute, and dehisced wounds, partial-thickness
burns, ulcers (such as diabetic, pressure, or venous insufficiency
ulcers), flaps, and grafts, for example. The term "tissue site" may
also refer to areas of tissue that are not necessarily wounded or
defective, but are instead areas in which it may be desired to add
or promote the growth of additional tissue. For example, reduced
pressure may be used in certain tissue areas to grow additional
tissue that may be harvested and transplanted to another tissue
location. In some illustrative embodiments, the tissue site 102 may
be a wound that extends through the epidermis 118, through a dermis
120, and into subcutaneous tissue 122, as shown in FIG. 1.
[0025] "Reduced pressure" generally refers to a pressure less than
a local ambient pressure, such as the ambient pressure in a local
environment external to the sealed therapeutic environment 124
provided by the drape 108. In many cases, the local ambient
pressure may also be the atmospheric pressure in a patient's
vicinity. Alternatively, the pressure may be less than a
hydrostatic pressure associated with tissue at the tissue site.
Unless otherwise indicated, values of pressure stated herein are
gauge pressures. Similarly, references to increases in reduced
pressure typically refer to a decrease in absolute pressure, while
decreases in reduced pressure typically refer to an increase in
absolute pressure.
[0026] A reduced-pressure source, such as the reduced-pressure
source 106, may be a reservoir of air at a reduced pressure, or may
be a manual or electrically-powered device that can reduce the
pressure in a sealed volume, such as a vacuum pump, a suction pump,
a wall-suction port available at many healthcare facilities, or a
micro-pump, for example. In some embodiments, a micro-pump may be a
pump configured to be coupled adjacent the drape 108. A
reduced-pressure source may be housed within or used in conjunction
with other components, such as sensors, processing units, alarm
indicators, memory, databases, software, display devices, or
operator interfaces that further facilitate reduced-pressure
therapy. While the amount and nature of reduced pressure applied to
a tissue site may vary according to therapeutic requirements, the
pressure typically ranges between -5 mm Hg (-667 Pa) and -500 mm Hg
(-66.7 kPa). Common therapeutic ranges are between -75 mm Hg (-9.9
kPa) and -300 mm Hg (-39.9 kPa). Generally, a reduced-pressure
source may be capable of reducing a pressure in a sealed
therapeutic environment to a therapy pressure. A therapy pressure
may be a reduced pressure at which a caregiver has determined
optimal therapy may be provided. In some embodiments, a
reduced-pressure source may use a therapy pressure as a target
pressure for reduced-pressure therapy. For example, a
reduced-pressure source may operate until a pressure in a sealed
therapeutic environment is approximately the therapy pressure. If a
pressure in a sealed therapeutic environment varies from a therapy
pressure, the reduced-pressure source may operate to lower the
pressure back to the therapy pressure.
[0027] A reduced pressure source may include a user interface. A
user interface may be a device configured to allow communication
between a controller and an environment external to a
reduced-pressure source. In some embodiments, an external
environment may include an operator or a computer system configured
to interface with a reduced-pressure source, for example. In some
embodiments, a user interface may receive a signal from a
controller and present the signal in a manner that may be
understood by an external environment. In some embodiments, a user
interface may receive signals from an external environment and, in
response, send signals to a controller.
[0028] In some embodiments, a user interface may be a graphical
user interface, a touchscreen, or one or more motion tracking
devices. A user interface may also include one or more display
screens, such as a liquid crystal display ("LCD"), lighting
devices, such as light emitting diodes ("LED") of various colors,
and audible indicators, such as a whistle, configured to emit a
sound that may be heard by an operator. A user interface may
further include one or more devices, such as knobs, buttons,
keyboards, remotes, touchscreens, ports that may be configured to
receive a discrete or continuous signal from another device, or
other similar devices; these devices may be configured to permit
the external environment to interact with the user interface. A
user interface may permit an external environment to select a
therapy to be performed with a reduced-pressure source. In some
embodiments, a user interface may display information for an
external environment such as a duration of therapy, a type of
therapy, an amount of reduced pressure being supplied, an amount of
instillation solution being provided, a fluid level of a container,
or a fluid level of a cartridge, for example.
[0029] A reduced-pressure source may also include one or more
pressure sensors. A pressure sensor, may be a piezoresistive strain
gauge, a capacitive sensor, an electromagnetic sensor, a
piezoelectric sensor, an optical sensor, or a potentiometric
sensor, for example. In some embodiments, a pressure sensor can
measure a strain caused by an applied pressure. A pressure sensor
may be calibrated by relating a known amount of strain to a known
pressure applied. The known relationship may be used to determine
an unknown applied pressure based on a measured amount of strain.
In some embodiments, a pressure sensor may include a receptacle
configured to receive an applied pressure.
[0030] A reduced-pressure source may include one or more moisture
sensors. A moisture sensor may be a device configured to measure a
relative humidity of a space. In some embodiments, a moisture
sensor may also be referred to as a hygrometer. In some
embodiments, a moisture sensor may be a capacitive humidity sensor
configured to measure the effect of humidity on a dielectric
constant of a polymer or metal oxide material. In other
embodiments, a moisture sensor may be a resistive humidity sensor
that is configured to measure an electrical resistance of a
material as it changes in response to humidity. In other
embodiments, other types of moisture sensors may be included in a
reduced-pressure source.
[0031] A reduced-pressure source may include one or more valves.
Generally, a valve may be configured to selectively permit fluid
flow through the valve. A valve may be a ball valve, a gate valve,
a butterfly valve, or other valve type that may be operated to
control fluid flow through the valve. Generally, a valve may
include a valve body having a flow passage, a valve member disposed
in the flow passage and operable to selectively block the flow
passage, and an actuator configured to operate the valve member. An
actuator may be configured to position the valve member in a closed
position, preventing fluid flow through the flow passage of the
valve; an open position, permitting fluid flow through the fluid
passage of the valve; or a metering position, permitting fluid flow
through the flow passage of the valve at a selected flow rate. In
some embodiments, the actuator may be a mechanical actuator
configured to be operated by an operator. In some embodiments, the
actuator may be an electromechanical actuator configured to be
operated in response to the receipt of a signal input. For example,
the actuator may include an electrical motor configured to receive
a signal from a controller. In response to the signal, the
electrical motor of the actuator may move the valve member of the
valve. In some embodiments, a valve may be configured to
selectively permit fluid communication between the reduced-pressure
source 106 and the dressing 104. In some embodiments, the
reduced-pressure source 106 may includes valves configured to
permit venting of the dressing 104 by allowing ambient air to flow
through the reduced-pressure source 106 to the dressing 104.
[0032] A reduced-pressure source may also include one or more flow
meters. A flow meter may be a device configured to determine a
fluid flow rate. A flow meter may include a mechanical flow meter,
a pressure based flow meter, an optical flow meter, an open channel
flow meter, a thermal mass flow meter, a vortex flow meter,
electromagnetic, ultrasonic and coriolis flow meters, or a laser
doppler flow meter, for example. A flow meter may determine a rate
of fluid flow through a valve and transmit a signal to a controller
corresponding to the determined flow rate.
[0033] A reduced-pressure source may include one or more
controllers, such as the controller 107, communicatively coupled to
components of the reduced-pressure source, such as a valve, a flow
meter, a sensor, a user interface, or a pump, for example, to
control operation of the same. As used herein, communicative
coupling may refer to a coupling between components that permits
the transmission of signals between the components. In some
embodiments, the signals may be discrete or continuous signals. A
discrete signal may be a signal representing a value at a
particular instance in a time period. A plurality of discrete
signals may be used to represent a changing value over a time
period. A continuous signal may be a signal that provides a value
for each instance in a time period. The signals may also be analog
signals or digital signals. An analog signal may be a continuous
signal that includes a time varying feature that represents another
time varying quantity. A digital signal may be a signal composed of
a sequence of discrete values.
[0034] In some embodiments, communicative coupling between a
controller and other devices may be one-way communication. In
one-way communication, signals may only be sent in one direction.
For example, a sensor may generate a signal that may be
communicated to a controller, but the controller may not be capable
of sending a signal to the sensor. In some embodiments,
communicative coupling between a controller and another device may
be two-way communication. In two-way communication, signals may be
sent in both directions. For example, a controller and a user
interface may be communicatively coupled so that the controller may
send and receive signals from the user interface. Similarly, a user
interface may send and receive signals from a controller. In some
embodiments, signal transmission between a controller and another
device may be referred to as the controller operating the device.
For example, interaction between a controller and a valve may be
referred to as the controller: operating the valve; placing the
valve in an open position, a closed position, or a metering
position; and opening the valve, closing the valve, or metering the
valve.
[0035] A controller may be a computing device or system, such as a
programmable logic controller, or a data processing system, for
example. In some embodiments, a controller may be configured to
receive input from one or more devices, such as a user interface, a
sensor, or a flow meter, for example. In some embodiments, a
controller may receive input, such as an electrical signal, from an
alternative source, such as through an electrical port, for
example.
[0036] In some embodiments, a controller may be a data processing
system. A data processing system suitable for storing and/or
executing program code may include at least one processor coupled
directly or indirectly to memory elements through a system bus. The
memory elements can include local memory employed during actual
execution of the program code, bulk storage, and cache memories
which provide temporary storage of at least some program code in
order to reduce the number of times code is retrieved from bulk
storage during execution.
[0037] In some embodiments, a controller may be a programmable
logic controller (PLC). A PLC may be a digital computer configured
to receive one or more inputs and send one or more outputs in
response to the one or more inputs. A PLC may include a
non-volatile memory configured to store programs or operational
instructions. In some embodiments, the non-volatile memory may be
operationally coupled to a battery-back up so that the non-volatile
memory retains the programs or operational instructions if the PLC
otherwise loses power. In some embodiments, a PLC may be configured
to receive discrete signals and continuous signals and produce
discrete and continuous signals in response.
[0038] A reduced-pressure source may also include a power source. A
power source may be a device that supplies electric power to an
electric load. A power source may include a battery, a direct
current (DC) power supply, an alternating current (AC) power
supply, a linear regulated power supply, or a switched-mode power
supply, for example. A power supply may supply electric power to a
controller, a sensor, a flow meter, a valve, a user interface, or a
pump, for example.
[0039] A tissue interface, such as the manifold 110, can generally
be adapted to contact a tissue site or other layers of a dressing,
such as the drape 108. A tissue interface may be partially or fully
in contact with a tissue site. If a tissue site is a wound, for
example, a tissue interface may partially or completely fill the
wound, or may be placed over the wound. A tissue interface may take
many forms, and may be many sizes, shapes, or thicknesses depending
on a variety of factors, such as the type of treatment being
implemented or the nature and size of a tissue site. For example,
the size and shape of a tissue interface may be adapted to the
contours of deep and irregular shaped tissue sites.
[0040] Generally, a manifold, such as the manifold 110, for
example, is a substance or structure adapted to distribute or
remove fluids from across a tissue site. A manifold may include
flow channels or pathways that can distribute fluids provided to
and removed from a tissue site. In one illustrative embodiment, the
flow channels or pathways may be interconnected to improve
distribution of fluids provided to or removed from a tissue site.
For example, a manifold may be an open-cell foam, porous tissue
collection, and other porous material such as gauze or felted mat
that generally includes structural elements arranged to form flow
channels. Liquids, gels, and other foams may also include or be
cured to include flow channels.
[0041] In one illustrative embodiment, the manifold 110 may be a
porous foam pad having interconnected cells adapted to distribute
reduced pressure across a tissue site. The foam material may be
either hydrophobic or hydrophilic. In one non-limiting example, the
manifold 110 may be reticulated polyurethane foam such as
GranuFoam.RTM. dressing available from Kinetic Concepts, Inc. of
San Antonio, Tex.
[0042] In some embodiments, such as embodiments in which the
manifold 110 may be made from a hydrophilic material, the manifold
110 may also wick fluid away from a tissue site while continuing to
distribute reduced pressure to the tissue site. The wicking
properties of the manifold 110 may draw fluid away from a tissue
site by capillary flow or other wicking mechanisms. An example of a
hydrophilic foam is a polyvinyl alcohol, open-cell foam such as
V.A.C. WhiteFoam.RTM. dressing available from Kinetic Concepts,
Inc. of San Antonio, Tex. Other hydrophilic foams may include those
made from polyether. Other foams that may exhibit hydrophilic
characteristics include hydrophobic foams that have been treated or
coated to provide hydrophilicity.
[0043] A tissue interface may further promote granulation at a
tissue site if pressure within a sealed therapeutic environment 124
is reduced. For example, any or all of the surfaces of the manifold
110 may have an uneven, coarse, or jagged profile that can induce
microstrains and stresses at a tissue site if reduced pressure is
applied through the manifold 110.
[0044] In some example embodiments, a tissue interface may be
constructed from bioresorbable materials. Suitable bioresorbable
materials may include, without limitation, a polymeric blend of
polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric
blend may also include without limitation polycarbonates,
polyfumarates, and capralactones. The tissue interface may further
serve as a scaffold for new cell-growth, or a scaffold material may
be used in conjunction with the tissue interface to promote
cell-growth. In general, a scaffold material may be a biocompatible
or biodegradable substance or structure used to enhance or promote
the growth of cells or formation of tissue, such as a
three-dimensional porous structure that provides a template for
cell growth. Illustrative examples of scaffold materials include
calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites,
carbonates, or processed allograft materials.
[0045] The drape 108 is an example of a sealing member. A sealing
member may be constructed from a material that can provide a fluid
seal between two environments or components, such as between a
therapeutic environment and a local external environment. A sealing
member may be, for example, an impermeable or semi-permeable,
elastomeric film or barrier that can provide a seal adequate to
maintain a reduced pressure at a tissue site for a given
reduced-pressure source. For semi-permeable materials, the
permeability generally should be low enough that a desired reduced
pressure may be maintained. An attachment device may be used to
attach a sealing member to an attachment surface, such as undamaged
epidermis, a gasket, or another sealing member. The attachment
device may take many forms. For example, an attachment device may
be a medically-acceptable, pressure-sensitive adhesive that extends
about a periphery of, a portion of, or an entirety of a sealing
member. Other example embodiments of an attachment device may
include a double-sided tape, paste, hydrocolloid, hydrogel,
silicone gel, organogel, or an acrylic adhesive.
[0046] A "container," such as the container 116, may be an
absorbent dressing having an absorbent that is placed in the fluid
path between a tissue site and a reduced-pressure source to receive
fluid from the tissue site. In some embodiments, an absorbent
dressing may place an absorbent adjacent a tissue site within a
sealed therapeutic environment.
[0047] The absorbent 126 may function to hold, stabilize, and/or
solidify fluids that may be collected from the tissue site 102. An
absorbent may be of the type referred to as "hydrogels,"
"super-absorbents," or "hydrocolloids," for example. When disposed
within the dressing 104, an absorbent may be formed into fibers or
spheres to manifold reduced pressure until the absorbent 126
becomes saturated. Spaces or voids between the fibers or spheres
may allow a reduced pressure that is supplied to the dressing 104
to be transferred within and through the absorbent 126 to the
manifold 110 and the tissue site 102. The absorbent 126 may be a
woven or non-woven material.
[0048] In some embodiments, an absorbent is formed of granular
absorbent components that are scatter-coated onto a paper
substrate. Scatter-coating involves spreading a granular absorbent
powder uniformly onto a textile substrate, such as paper. The
substrate, having the granular absorbent powder disposed thereon,
may be passed through an oven to cure the powder and cause the
powder to adhere to the paper substrate. The cured granular
absorbent powder and substrate are passed through a calender
machine to provide a smooth uniform surface to an absorbent.
[0049] In some exemplary embodiments, an absorbent may be formed of
a superabsorbent polymer (SAP). Generally, relative to their mass,
SAPs can absorb and retain large quantities of liquid, and in
particular water. In some embodiments, SAPs may be formed from
sodium polyacrylate. Sodium polyacrylate may be a sodium salt of
polyacrylic acid. Sodium polyacrylate may be an anionic
polyelectrolyte with negatively charged carboxylic groups in its
main chain. SAPs may be formed in several ways, for example, by gel
polymerization, solution polymerization, or suspension
polymerization. Gel polymerization involves blending of acrylic
acid, water, cross-linking agents, and UV initiator chemicals. The
blended mixture is then placed into a reactor where the mixture is
exposed to UV light to cause crosslinking reactions that form the
SAP. The mixture may be dried and shredded before subsequent
packaging and/or distribution. Solution polymerization involves a
water based monomer solution that produces a mass of reactant
polymerized gel. The monomer solution undergoes an exothermic
reaction that drives the crosslinking of the monomers. Following
the crosslinking process, the reactant polymer gel is chopped,
dried, and ground to its final granule size. Suspension
polymerization involves a water-based reactant suspended in a
hydrocarbon-based solvent. However, the suspension polymerization
process must be tightly controlled and is not often used.
[0050] High absorbing SAPs are based on ionic crosslinked
hydrophilic polymers such as acrylics and acrylamides in the form
of salts or free acids. SAPs absorb liquids by bonding with water
molecules through hydrogen bonding. Hydrogen bonding involves the
interaction of a polar hydrogen atom with an electronegative atom.
As a result, SAPs absorb water based on the ability of the hydrogen
atoms in each water molecule to bond with the hydrophilic polymers
of the SAP having electronegative ionic components. Because the
SAPs are ionic, they are affected by the soluble ionic components
within the solution being absorbed and will, for example, absorb
less saline than pure water, the sodium and chloride ions may block
some of the water absorbing sites on the SAPs. For example, an SAP
may absorb and retain de-ionized water up to 500 times the weight
of the dry SAP. In volumetric terms, an SAP may absorb fluid
volumes as high as 30 to 60 times the dry volume of the SAP. Other
fluids having a higher ionic concentration may be absorbed at lower
quantities.
[0051] In some exemplary embodiments, the absorbent 126 may have an
area density of 800 grams per square meter (gsm), such as Texsus
FP2325, for example. Area density may also be referred to as paper
density and material density, for example. Area density may refer
to a mass of a product per unit area of a type of fabric, paper, or
paperboard. In some exemplary embodiments, the area density of the
absorbent 126 may refer to the amount of SAP per square meter of a
fiber substrate that forms the base of the absorbent 126. In some
exemplary embodiments, the absorbent 126 may have an area density
of 400 gsm, such as Texsus FP 2326, for example. In other exemplary
embodiments, the absorbent 126 may be BASF 402C, Technical
Absorbents 2317 available from Technical Absorbents
(www.techabsorbents.com), sodium polyacrylate super absorbers,
cellulosics (carboxy methyl cellulose and salts such as sodium
CMC), or alginates.
[0052] The absorbent 126 may also have a free swell capacity. The
free swell capacity may refer to the amount of deionized water that
the SAP of the absorbent 126 may absorb per amount of the SAP and
may be measured in grams/gram (g/g). In some embodiments, the
absorbent 126 may have a free swell capacity of about 30 grams of
water absorbed per gram of SAP, for example.
[0053] In some embodiments, the upstream layer 128 and the
downstream layer 130 may have perimeter dimensions that are larger
than the perimeter dimensions of the absorbent 126 so that the
upstream layer 128 and the downstream layer 130 collectively
surround the absorbent 126. For example, if the absorbent 126 is
positioned between the upstream layer 128 and the downstream layer
130 and the center portions of the absorbent 126, the upstream
layer 128 and the downstream layer 130 are aligned, the upstream
layer 128 and the downstream layer 130 may extend beyond the
perimeter of the absorbent 126. Peripheral portions of the upstream
layer 128 and the downstream layer 130 may be coupled so that the
upstream layer 128 and the downstream layer 130 enclose the
absorbent 126. The upstream layer 128 and the downstream layer 130
may be coupled by high frequency welding, ultrasonic welding, heat
welding, or impulse welding, for example. In other embodiments, the
upstream layer 128 and the downstream layer 130 may be coupled by
bonding or folding, for example.
[0054] The upstream layer 128 may be formed of non-woven material.
A non-woven material may be a fabric-like material that includes
long fibers that are bonded together. In some embodiments, the
fibers may be bonded by one or more of chemical bonding, mechanical
bonding, heat bonding, or solvent treatment bonding. Generally,
small fibers are formed into a sheet or web and then bound with a
mechanical process, such as with an adhesive, or in a thermal
process where a binder is melted onto the web. In some embodiments,
the upstream layer 128 may have a polyester fibrous porous
structure. The upstream layer 128 may be porous, but preferably not
perforated. In some embodiments, the upstream layer 128 may have an
area density between about 80 gsm and about 150 gsm. In other
embodiments, the area density may be lower or greater depending on
the particular application of the container 116. In some
embodiments, the upstream layer 128 may be formed of Libeltex TDL2,
for example. In other embodiments, the upstream layer 128 may be
formed of Libeltex TL4.
[0055] The downstream layer 130 may also be formed of a non-woven
material. In some exemplary embodiments, the downstream layer 130
may have a polyester fibrous porous structure. The downstream layer
130 may be porous, but preferably not perforated. In some
embodiments, the downstream layer 130 may have an area density
between about 80 gsm and about 150 gsm. In other embodiments, the
area density may be lower or greater depending on the particular
application of the container 116. In some embodiments, the area
density of the downstream layer 130 may be greater than the area
density of the upstream layer 128. In other embodiments, the area
density of the downstream layer 130 may be less than the area
density of the upstream layer 128. In some embodiments, the
upstream layer 128 and the downstream layer 130 may have a same
area density. The downstream layer 130 may have a thickness greater
than, less than, or equal to a thickness of the upstream layer 128.
In some embodiments, the downstream layer 130 may be formed of
Libeltex TL4. In other embodiments, the downstream layer 130 may be
formed of Libeltex TDL2.
[0056] The upstream layer 128 and the downstream layer 130 contain
the absorbent 126 and may reduce SAP loss during manufacturing,
shipping, and use of the container 116. For example, if the
container 116 is used at the tissue site 102, containment of the
absorbent material may limit migration of the granular absorbent
components into the tissue site 102. If the tissue site 102 is
small, the container 116 may also aid the manifold 110 in the
distribution of reduced pressure to the tissue site 102. The
upstream layer 128 and the downstream layer 130 may also wick
fluids from the tissue site 102 into the absorbent 126. The
upstream layer 128 and the downstream layer 130 may prevent the
loss of structural integrity associated with using scatter coated
absorbent material to form the absorbent 126 that may often lead to
more frequent replacement of the container 116.
[0057] Reduced pressure developed by the reduced-pressure source
106 may be delivered through the tube 112 to the connector 114. In
some embodiments, the connector 114 may be a T.R.A.C..RTM. Pad or
Sensa T.R.A.C..RTM. Pad available from Kinetic Concepts, Inc. (KCI)
of San Antonio, Tex. The connector 114 may allow the reduced
pressure to be delivered to the sealed therapeutic environment 124.
In other embodiments, the connector 114 may also be a conduit
inserted through the drape 108. The filter 132 may comprise a
hydrophobic material substantially filling the fluid channel
through the connector 114 and adapted to limit passage of liquids
through the connector 114 into the tube 112.
[0058] The provision of reduced-pressure therapy with
reduced-pressure therapy systems, such as the reduced-pressure
therapy system 100, is increasingly being performed with smaller
therapy devices that use battery power rather than a connection to
an electrical outlet. Smaller therapy devices may also necessitate
use of absorbent dressings to store fluid from the tissue site.
Using an absorbent dressing rather than a separate fluid container
may significantly decrease the amount of fluid that can be stored
compared to a separate container. If the absorbent dressing is
saturated, the reduced-pressure therapy must be stopped and the
absorbent in the dressing replaced before reduced-pressure therapy
may continue. Frequent removal and replacement of the dressing may
cause irritation to a tissue site that could prolong healing times
and cause pain to a patient. Frequent removal and replacement of
the dressing may also increase the cost of providing
reduced-pressure therapy.
[0059] In addition, an absorbent of an absorbent dressing may
expand or swell as the absorbent absorbs fluid. If an absorbent is
placed under a load, such as having a weight pressed against it or
by being placed under a reduced pressure, the ability of the
absorbent to expand may be decreased. If the ability of an
absorbent to expand is decreased, the absorbent may absorb an
amount of fluid that is less than a full fluid capacity of the
absorbent. As a result, an absorbent dressing may need to be
frequently removed and replaced to continue reduced-pressure
therapy, which can increase healing times, pain, and costs. For
example, an absorbent dressing, such as the dressing 104 may be
coupled to the tissue site 102. The reduced-pressure source 106 may
be fluidly coupled to the dressing 104 and operated to supply the
sealed therapeutic environment 124 with a reduced pressure. If
reduced pressure is supplied to the sealed therapeutic environment
124, a volume of the sealed therapeutic environment 124 may
decrease, compressing the container 116 and the absorbent 126
between the manifold 110 and the drape 108. Compression of the
container 116 and the absorbent 126 generally decreases the
absorption capacity of the absorbent 126 as described above. To
increase a fluid capacity of an absorbent dressing, and thereby
decrease the frequency of dressing changes, the absorbent of the
absorbent dressing can be increased in thickness. However,
increasing the thickness of the absorbent may negatively affect the
ability of a reduced-pressure source to provide reduced-pressure
therapy.
[0060] As disclosed herein, the reduced-pressure therapy system 100
can overcome these challenges and others by increasing absorbent
capacity through intermittent application of reduced pressure. In
some embodiments, for example, the intermittent application of
reduced pressure may include decreasing reduced pressure to manage
fluid absorption. In yet more particular embodiments, a
reduced-pressure source may provide reduced pressure that is
allowed to decay periodically for a predetermined time period. In
some embodiments, reduced pressure provided by a reduced-pressure
source may be allowed to decay to an ambient pressure from the
therapy pressure. Decay of reduced pressure or reduced-pressure
decay may refer to the gradual decrease of reduced pressure in the
sealed therapeutic environment 124 in the absence of a supply of
reduced pressure. A decrease in reduced pressure in the sealed
therapeutic environment 124 may occur as fluid from the tissue site
102 is drawn into the sealed therapeutic environment 124 by the
supplied reduced pressure. A decrease in reduced pressure in the
sealed therapeutic environment 124 may also occur due to gas
permeating through the drape 108 into the sealed therapeutic
environment 124 from the ambient environment. A decrease in reduced
pressure in the sealed therapeutic environment 124 may also be
caused by a leak between the drape 108 and the epidermis 118.
[0061] In some embodiments, the reduced-pressure source 106 may be
fluidly coupled to an absorbent dressing, such as the dressing 104,
having the absorbent 126. The reduced-pressure source 106 may
control the expansion of the absorbent 126 by controlling the
application of reduced pressure to the tissue site 102. In some
embodiments, the reduced-pressure source 106 may reduce pressure in
the sealed therapeutic environment 124 to the therapy pressure,
compressing the absorbent 126. Once the therapy pressure is
reached, the reduced-pressure source 106 may decrease the reduced
pressure by allowing the reduced pressure in the sealed therapeutic
environment 124 to decay. Decay of the reduced-pressure in the
sealed therapeutic environment 124 may allow the absorbent 126 to
expand. In some embodiments, if the pressure in the sealed
therapeutic environment 124 reaches an ambient pressure, the
reduced-pressure source 106 may be operated to supply reduced
pressure until the pressure in the sealed therapeutic environment
124 reaches the therapy pressure. Each time the pressure in the
sealed therapeutic environment 124 reaches the therapy pressure,
the reduced pressure may be allowed to decay, and the cycle may be
repeated periodically until the reduced-pressure therapy concludes.
In other embodiments, the pressure in the sealed therapeutic
environment 124 may be allowed to decay to a nominal reduced
pressure. A nominal reduced pressure may be a reduced pressure that
is greater than the ambient pressure but that is less than the
therapy pressure. A nominal reduced pressure may be selected by an
operator of the reduced-pressure therapy system 100.
[0062] FIG. 2 is a line chart of reduced pressure that is applied
in a sealed therapeutic environment, illustrating details that may
be associated with some embodiments. The vertical axis represents
an amount of reduced pressure in mm Hg, and the horizontal axis
represents an amount of time in minutes. FIG. 2 illustrates a
pressure profile 202 of a pressure in a sealed therapeutic
environment, such as the sealed therapeutic environment 124 during
reduced-pressure therapy. As shown, the pressure profile 202
illustrates a substantially constant level of reduced-pressure. The
pressure profile 202 may be maintained at about 125 mm Hg reduced
pressure for the duration of reduced-pressure therapy. For example,
the reduced-pressure source 106 may maintain a reduced pressure of
about 125 mm Hg until the reduced-pressure source 106 is shut off
at about 2100 minutes. After the reduced-pressure source 106 is
shut off, the reduced pressure in the sealed therapeutic
environment 124 may decay to ambient pressure.
[0063] FIG. 2 also illustrates another pressure profile 204 of the
pressure in a sealed therapeutic environment. As shown by the
pressure profile 204, the pressure in a sealed therapeutic
environment may be reduced to about the therapy pressure. For
example, the pressure profile 204 may have a draw-down 206 during
which pressure is reduced to a therapy pressure 208. The pressure
may be allowed to decay, as shown by a decay 210. For example, the
pressure profile 204 may increase to about 125 mm Hg of reduced
pressure while the reduced-pressure source 106 is operated, as
shown during the draw-down 206. The reduced pressure may decrease
during the decay 210 until about 1200 minutes when the pressure may
again be reduced to about the therapy pressure. In some
embodiments, the pressure profile 204 may decay to a nominal
pressure that is about 25 mm Hg reduced pressure. In other
embodiments, the pressure profile 204 may decay to an ambient
pressure of about 0 mm Hg reduced pressure. The process may repeat
until the conclusion of reduced-pressure therapy.
[0064] Referring again to FIG. 1, if the pressure is reduced in the
sealed therapeutic environment 124, the drape 108 may compress the
container 116 and the absorbent 126 against the manifold 110. For
example, during the draw-down 206, the drape 108 may compress the
container 116 against the manifold 110. As the reduced pressure
decays during the decay 210, the amount of compression applied by
the drape 108 may gradually decrease in proportion to the decrease
in reduced pressure. The decreasing compression allows the
absorbent 126 to expand. As the absorbent 126 expands, the
absorbent 126 may distribute or redistribute fluid within a matrix
of the absorbent 126. For example, the absorbent 126 may
redistribute fluid into superabsorbent particles and between
superabsorbent particles of the absorbent 126. Redistribution of
fluid within the absorbent 126 may move fluid into areas not
previously saturated and may allow saturated areas to become less
saturated. If the reduced-pressure source 106 again supplies
reduced pressure, the drape 108 may again compress the absorbent
126 against the manifold 110. The fluid previously absorbed by the
absorbent 126 may prevent the absorbent 126 from being compressed
as much as during the previous application of reduced pressure by
the reduced-pressure source 106. If the therapy pressure is reached
and the reduced-pressure source 106 stops supplying reduced
pressure, allowing the reduced pressure in the sealed therapeutic
environment 124 to decay, the absorbent 126 may again expand. Each
compression and expansion of the absorbent 126 allows the absorbent
126 to increase its overall volume for fluid absorption while still
providing reduced-pressure therapy.
[0065] In a working example, a first reduced-pressure source, such
as the reduced-pressure source 106 was coupled to a first dressing,
such as the dressing 104. The first reduced-pressure source was
operated at a constant level of reduced pressure, about 125 mm Hg,
for a therapy period, about 2400 minutes. The constant level of
reduced pressure produced a pressure profile similar to the
pressure profile 202. Fluid was supplied to the first dressing in
periodic intervals. In the working example, an absorbent, such as
the absorbent 126 having SAPs, absorbed approximately 50 cubic
centimeters (cc) of fluid. A second reduced-pressure source, such
as the reduced-pressure source 106, was fluidly coupled to a second
dressing, such as the dressing 104, having an absorbent, such as
the absorbent 126 having SAPs. The second reduced-pressure source
was operated to reduce the pressure in sealed therapeutic
environment formed by the second dressing to the therapy pressure,
about 125 mm Hg. The reduced pressure was then allowed to decay to
about 25 mm Hg before the second reduced-pressure source was
operated to increase the reduced pressure to about 125 mm Hg. The
cycle was repeated three times and produced a pressure profile
similar to the pressure profile 204. By operating the second
reduced-pressure source so that the reduced pressure in the sealed
therapeutic environment decays, for example, as illustrated by the
pressure profile 204, the second dressing experienced an increase
of about 10% in the fluid storage capacity. For example, the second
dressing subjected to the pressure profile 204 was able to absorb
approximately 55 cc of fluid. By reapplying reduced pressure
following the decay of the pressure in a sealed therapeutic
environment, a tissue site may still experience the benefits of
reduced pressure therapy while increasing a fluid absorption
capacity to minimize the side effects of repeated dressing
changes.
[0066] In some embodiments, the reduced-pressure source 106 may be
operated in an intermittent mode of reduced-pressure therapy. An
intermittent mode of reduced-pressure therapy may include a cyclic
operation of the reduced-pressure source 106 so that the
reduced-pressure source 106 increases reduced pressure for a
periodic interval of time and decreases reduced pressure for period
intervals of time, such as in the pressure profile 204. Operating
the reduced-pressure source 106 in the intermittent mode may
further increase the fluid absorption capacity of the absorbent
126. For example, the reduced-pressure source 106 may operate to
provide reduced pressure for intervals of one minute and stop
providing reduced pressure for intervals of two minutes, decreasing
the reduced pressure. For example, during the intermittent mode,
the reduced-pressure source 106 may compress the absorbent 126 for
one minute during the application of reduced pressure and expand
the absorbent 126 for two minutes during a period of decay.
[0067] FIG. 3 is a line chart of reduced pressure that may be
applied in the sealed therapeutic environment 124, illustrating
details that may be associated with some embodiments. The vertical
axis represents an amount of reduced pressure in mm Hg, and the
horizontal axis represents an amount of time in minutes. The
pressure profile 202 of FIG. 2 is provided for reference. The
reduced-pressure source 106 may be operated in an intermittent mode
so that reduced pressure is supplied for one minute and the
reduced-pressure source 106 is turned off for one minute, a 1/1
intermittent mode. The 1/1 intermittent mode may produce a pressure
profile 304 in the sealed therapeutic environment 124. In the
example embodiment of FIG. 3, if the reduced-pressure source 106 is
operating, the reduced pressure may increase to about 125 mm Hg. If
the reduced-pressure source 106 is not operating, the reduced
pressure may decay to about 25 mm Hg. During the one minute that
the reduced-pressure source 106 operates, the drape 108 may
compress the container 116 against the manifold 110, and during the
one minute that the reduced-pressure source 106 is not operating,
the absorbent 126 of the container 116 may expand as the reduced
pressure decays. In some embodiments, the reduced-pressure source
106 may be operated to decrease the reduced pressure or increase
the decay rate by permitting ambient pressure to flow through the
reduced-pressure source 106 to the sealed therapeutic environment
124.
[0068] FIG. 4 is a line chart of reduced pressure that may be
applied in the sealed therapeutic environment 124, illustrating
details that may be associated with some embodiments. The vertical
axis represents an amount of reduced pressure in mm Hg, and the
horizontal axis represents an amount of time in minutes. The
pressure profile 202 of FIG. 2 is also provided in FIG. 4 for
reference. For example, a pressure profile 404 can be provided if
the reduced-pressure source 106 is operated in an intermittent mode
so that reduced pressure is supplied for one minute and the
reduced-pressure source 106 is turned off for five minutes, a 1/5
intermittent mode. In the example of FIG. 4, the pressure profile
404 illustrates an increase in the reduced pressure in the sealed
therapeutic environment to about 125 mm Hg reduced pressure and a
decrease in the reduced pressure to about 0 mm Hg reduced pressure.
In some embodiments the sealed therapeutic environment 124 may
remain at about 0 mm Hg until the end of the five minute period.
During the one minute intervals that the reduced-pressure source
106 operates, the drape 108 may compress the container 116 against
the manifold 110, and during the five minute intervals that the
reduced-pressure source 106 is not operating, the absorbent 126 of
the container 116 may expand. In some embodiments, once the
pressure in the sealed therapeutic environment 124 reaches 0 mm Hg,
the absorbent 126 may swell as more fluid is absorbed. In some
embodiments, the reduced-pressure source 106 may be operated to
increase the decay rate by permitting ambient pressure to flow
through the reduced-pressure source 106 to the sealed therapeutic
environment 124.
[0069] In a working example using the 1/1 and the 1/5 intermittent
modes, a first dressing, similar to the dressing 104 having the
absorbent 126 formed of SAPs, was fluidly coupled to a first
reduced-pressure source, similar to the reduced-pressure source
106, and provided a constant level of reduced pressure. In the
working example, the reduced pressure in a sealed therapeutic
environment formed by the first dressing was maintained at about
125 mm Hg for the duration of the reduced-pressure therapy. A
second dressing, similar to the dressing 104 having the absorbent
126 formed from SAPs, was coupled to a second reduced-pressure
source, similar to the reduced-pressure source 106, and operated in
an intermittent mode. The second dressing experienced an increase
of fluid absorption between about 15% and about 36% in the
intermittent mode of reduced-pressure therapy when compared to the
constant application of reduced pressure. For example, the 1/1
intermittent mode with a dressing positioned in a vertical position
increased in fluid storage capacity by about 15%. The 1/1
intermittent mode with a dressing positioned in an inverted
position increased in fluid storage capacity by about 36%. When the
therapy interval increased to 1 minute of reduced pressure and 5
minutes of no reduced pressure, the storage capacity increased
further in both the vertical and inverted dressing positions.
[0070] FIG. 5 illustrates a flow chart 500 of logical operations
that can be implement in some embodiments of the reduced-pressure
therapy system 100 of FIG. 1 during reduced-pressure therapy. For
example, the operations may be implemented by a controller, such as
the controller 107, configured to execute the operations. At block
502, a dressing having an absorbent may be positioned proximate a
tissue site. For example, the dressing 104 having the absorbent 126
may be positioned adjacent the tissue site 102 to form the sealed
therapeutic environment 124. At block 504, a reduced-pressure
source may reduce pressure adjacent the tissue site to a therapy
pressure. For example, the reduced-pressure source 106 may provide
reduced pressure to the sealed therapeutic environment 124 until a
pressure in the sealed therapeutic environment 124 is about the
therapy pressure. At block 506, the reduced-pressure source may
stop providing reduced pressure. For example, the reduced-pressure
source 106 may stop providing reduced pressure to the sealed
therapeutic environment 124. At block 508, the system can determine
if the pressure adjacent the tissue site is about an ambient
pressure. For example, a pressure sensor in the reduced-pressure
source 106 may determine if the pressure in the sealed therapeutic
environment 124 is about an ambient pressure. If the pressure
adjacent the tissue site is not about the ambient pressure at block
508 (NO), the system can wait for a predetermined time period at
block 509 and continue at block 508, where the system can determine
if the pressure adjacent the tissue site is about an ambient
pressure. If the pressure adjacent the tissue site is about the
ambient pressure at block 508 (YES), the system can continue to
block 510. At block 510, the system can determine if the absorbent
is saturated. For example, a moisture sensor of the
reduced-pressure source 106 may determine if absorbent 126 is
saturated. If the absorbent is not saturated at block 510 (NO), the
system can continue at block 504 where reduced pressure is provided
until the pressure in the sealed therapeutic environment is about
the therapy pressure. If the absorbent is saturated at block 510
(YES), the system can stop.
[0071] FIG. 6 illustrates a flow chart 600 of logical operations
that can be implemented in some embodiments of the reduced-pressure
therapy system 100 of FIG. 1 during reduced-pressure therapy. For
example, the operations may be implement by a controller, such as
the controller 107, configured to execute the operations. At block
602, a dressing having an absorbent may be positioned proximate a
tissue site. For example, the dressing 104 having the absorbent 126
may be positioned adjacent the tissue site 102 to form the sealed
therapeutic environment 124. At block 604, a reduced-pressure
source may provide reduced pressure for a predetermined time
period. For example, the reduced-pressure source 106 may provide
reduced pressure to the sealed therapeutic environment 124 for a
predetermined time interval. In some embodiments, the predetermined
time interval may be between about 1 minute and about 20 minutes.
At block 606, the reduced-pressure source may stop providing
reduced pressure for a predetermined time period. For example, the
reduced-pressure source 106 may stop providing reduced pressure to
the sealed therapeutic environment 124 for a predetermined time
interval. In some embodiments, the predetermined time interval of
no reduced pressure may be between about 1 minute and about 20
minutes. At block 608, the system can determine if the absorbent is
saturated. If the absorbent is not saturated at block 608 (NO), the
system can continue at block 604 where reduced pressure is provided
for the predetermined interval. If the absorbent is saturated at
block 608 (YES), the system can stop.
[0072] FIG. 7 illustrates a flow chart 700 of logical operations
that can be implemented in some embodiments of the reduced-pressure
therapy system 100 of FIG. 1 during reduced-pressure therapy. For
example, the operations may be implement by a controller, such as
the controller 107, configured to execute the operations. At block
702, a dressing having an absorbent may be positioned proximate a
tissue site. For example, the dressing 104 having the absorbent 126
may be positioned adjacent the tissue site 102 to form the sealed
therapeutic environment 124. At block 704, a reduced-pressure
source may compress the superabsorbent. For example, the
reduced-pressure source 106 may provide reduced pressure to the
sealed therapeutic environment 124, compressing the absorbent 126.
At block 706, the reduced-pressure source may expand the absorbent
126. For example, the reduced-pressure source 106 may provide no
reduced pressure to the sealed therapeutic environment 124,
permitting the absorbent 126 to expand as the reduced pressure in
the sealed therapeutic environment 124 decays. At block 708, the
system can determine if the absorbent is saturated. If the
absorbent is not saturated at block 708 (NO), the system can
continue at block 704 where the absorbent is compressed. If the
absorbent is saturated at block 708 (YES), the system can stop.
[0073] The systems and methods described herein may provide
significant advantages, some of which have already been mentioned.
For example, the reduced-pressure system may provide a dressing
having an increased fluid absorption capacity without requiring an
increase in a thickness of the absorbent. Furthermore, the
reduced-pressure system may increase the fluid absorption capacity
of the absorbent while continuing to provide reduced-pressure
therapy.
[0074] Although the certain features, aspects, operations, and
their advantages have been disclosed in the context of certain
illustrative, non-limiting embodiments, it should be understood
that various changes, substitutions, permutations, and alterations
can be made without departing from the scope of the invention as
defined by the appended claims. It will be appreciated that
features that may be described in connection to one embodiment may
also be applicable to other embodiments. It will also be understood
that the benefits and advantages described above may relate to one
embodiment or may relate to several embodiments. It will further be
understood that reference to "an" item refers to one or more of
those items.
[0075] The steps of the methods described herein may be carried out
in a suitable order, or simultaneously where appropriate.
[0076] Where appropriate, aspects of the embodiments described
above may be combined with aspects of the other embodiments
described to form further examples having comparable or different
properties and addressing the same or different problems.
[0077] It will be understood that the embodiments described herein
are given by way of example only and that various modifications may
be made by those skilled in the art. The above specification,
examples and data provide a complete description of the structure
and use of exemplary embodiments. Although various embodiments have
been described above with a certain degree of particularity, or
with reference to one or more individual illustrations, those
skilled in the art could make numerous alterations to the example
embodiments without departing from the scope of the claims.
* * * * *